ARCHIVES

New Clinical Trials Monitoring Program To Site Visit PIs Every Three Years

This article is from The Cancer Letter archive.

Vol. 08 No. 31 | July 30, 1982

Download PDF Visit The Full Archive

Related Articles

Henderson Committee Final Recommendation Made On P01s

February 10, 1984

Clinical Trials: Breast Cancer Prevention Trial requires Fewer Participants, NCI Says

September 6, 1996

Pittsburgh Broadens Misconduct Inquiry

June 3, 1994

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

July 27, 2012

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

July 30, 2004

DCE Board Gives Concept Approval To Eight Contract Recompetitions

July 20, 1984